Abstract
Background. Patients with end-stage renal disease who developed H1N1 infections have an increased risk of morbidity and mortality. In light of the high incidence of H1N1 infections in renal replacement therapy patients in Brunei Darussalam, an Oseltamivir (Tamiflu) prophylactic dosing regimen of 75 mg every 5 days for renal replacement therapy patients was initiated by the Ministry of Health in August 2009. The regime was used to serve as a bridge towards an anticipated nationwide vaccination programme that was due in September 2009. This study aimed to evaluate the side effects, factors that might influence the side effects profile and compliance of the dialysis patients that had undergone the month-long chemoprophylactic regime. Methods. A cross-sectional study was carried out on the dialysis patients that had undergone the oseltamivir prophylactic regime, which involved distribution of questionnaires to participants after the regime was completed. Results. Three hundred and thirty-three patients participated in this study. 25.7% of sample participants reported at least one side effect (experienced during the regime). 97% of participants were found to have reported three side effect types or less. The most frequent side effects reported were nausea (9.4%), abdominal pain (9.1%) and dizziness (9.1%). Age, gender, dialysis types, serum haemoglobin, serum albumin and dialysis clearance measurements were found to have no significant associations with the frequency of participants that had reported side effects. 11.2% of sample participants made up the non-compliant group. The top two reasons for not completing the medication were participants' perceived side effects (24.3%) and forgetting to take their medications (56.8%). Conclusions. Side effects were found to be mild and tolerable by participants, with no life-threatening events. The study showed that high compliance of this regime can be achieved. These results, together with no incidence of H1N1 cases in the sample participants, showed that the dosing regimen of 75 mg every 5 days in both haemodialysis and continuous ambulatory peritoneal dialysis pa-
Introduction
Background H1N1 in Brunei. Brunei Darussalam reported its first H1N1 case on 20 June 2009 and its first casualty case related to H1N1 (a 12-year-old girl, who had multiple chronic complications) on 2 July 2009 [1] . On 13 July 2009, H1N1 infection was first confirmed in a dialysis patient in Brunei. By early August 2009, Brunei had recorded 12 dialysis patients diagnosed with the H1N1 infection. The rapidity of H1N1 spread in the dialysis population raised concerns regarding the susceptibility and vulnerability of the local dialysis population. All the patients had infections severe enough to warrant admissions to isolation facilities in hospitals for treatment and dialysis. In light of the worrying nature of the spread, a policy decision was undertaken by the Ministry of Health to provide short-term prophylaxis to all dialysis patients as a bridge towards an anticipated nationwide vaccination programme that was due to start in September 2009. Issues regarding resistance of H1N1 prophylaxis were considered by the local authorities but it was thought at that time, the risks of morbidity and mortality potentially associated with H1N1-afflicted patients outweigh the risks of resistance especially as prophylaxis was only meant to last for 1 month until H1N1 vaccination is made available.
Oseltamivir (Tamiflu). Oseltamivir phosphate, an ethyl ester prodrug, converts to its active form, oseltamivir carboxylate by esterases, enzymes located predominantly in the liver. It is this active form of oseltamivir that inhibits influenza virus neuraminidase, which is needed by the virus to exit from its host cells [2] .
It has been found from clinical studies of adult patients that oseltamivir treatment reduces influenza illness by about a day and reduces incidence of laboratory-confirmed clinical influenza by ∼4% [2] . Roche [2] has also recommended oral dosage of oseltamivir for treatment for patients ≥13 years to be 75 mg twice daily over a length of 5 days and 75 mg once daily for at least 10 days when given for prophylactic purposes. The drug has been found to be generally well tolerated by patients (whose age are within the Food and Drug Administration-approved age range), with frequently reported side effects such as nausea, vomiting, diarrhoea, abdominal pain, with rarer cases of anaphylaxis and serious skin reactions [2, 3] . Post-marketing reports of side effects have included those that were neuropsychiatric in nature, which according to Roche, were uncommon events [2] .
Oseltamivir was one of the antivirals recommended and emphasized for use by the World Health Organization in both treatment and prophylaxis of H1N1 infection [4] . Oseltamivir chemoprophylaxis became particularly important in the management of the early stages of the H1N1 (influenza A) during its outbreak in 2009 especially because of the lack of an effective vaccination at the time. Oseltamivir had since seen an increase in its use internationally. This was also partly due to increase in H1N1 strains being resistant to the antiviral drugs, amantadine and rimantadine [3] .
Oseltamivir in renal impairment. The symptoms of H1N1 are considered mild in the general public. However, in the patient with renal failure, the complications of contracting H1N1 can become serious and life threatening. Marcelli et al. [5] reported that H1N1 patients who were on chronic dialysis treatment have a 10-fold higher mortality rate when compared with the general population. Vaillant et al. [6] went on to report that chronic renal impairment is a risk factor of mortality in H1N1 patients.
Excretion of oseltamivir is primarily via the kidneys and therefore patients with impaired renal function experience decreased renal clearance and increased systemic exposure to oseltamivir as the severity of renal impairment increases [7] . Adjustments, thus, have to be made to dosages and intake frequency to reduce complications that could arise due to the poor renal performance of the patients.
A regime model of 75 mg every 5 days for both continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis (HD) patients for a month was proposed by the Ministry of Health and initiated in the month of August of 2009 for the other dialysis patients not diagnosed with H1N1. The choice of dosing was influenced by the recommendations made by Roche [2] , who advised a prophylaxis dosing of 75 mg every other day for patients with creatinine clearance between 10 and 30 mL/min. As all our target patients were dialysis patients with creatinine clearance of <10 mL/min, it was thought reasonable to decrease the frequency of dosing to once every 5 days. The Ministry of Health authorities decided for the month-long prophylactic course, as they had anticipated a wane in the influenza spread in Brunei by early September 2009. It was also to serve as a bridge between them and the availability of the expected H1N1 vaccine in September 2009.
The purpose of this study is to assess the safety of the proposed dosing regimen, by assessing the side effect profile in the participants of this study.
Aims
To assess the side effects of the month-long oseltamivir prophylactic regime (75 mg every 5 days) when used as prophylaxis against H1N1 in dialysis (CAPD and HD) patients.
Three specific objectives are
(1) to identify and estimate the frequency of side effects of participants of the month-long oseltamivir prophylactic regime, (2) to determine possible factors that had significant associations with oseltamivir side effects and (3) to evaluate compliance of the participants and the reasons for non-compliance of the month-long oseltamivir prophylactic regime
Materials and methods
End-stage renal disease (ESRD) patients of all the dialysis centres in Brunei, either undergoing routine HD or CAPD and who have been prescribed and taken at least one dose of the oseltamivir prophylactic regime in August 2009 are included in the study. Renal transplant patients are not included because of the variability of their estimated glomerular filtration rates that may account for unpredictable clearances of the drug. All ESRD patients attending their respective dialysis clinics were approached by assigned nurses and explained about the study. Side effects identified in the published materials [2, 8] were used to develop the questionnaire. Early versions of the questionnaire were pretested on a few dialysis patients and nurses in the RIPAS hospital dialysis clinic, and revisions followed suit with feedback. There were four main areas explored in the questionnaire:
(1) Basic demographic background of the participant which included dialysis treatment type and dialysis centre.
(2) Compliance of the dialysis patient to the oseltamivir medications of the prophylactic regime. This section asked the patient if he or she had completed the full course of the regime and reasons for non-compliance if that were the case. Reasons included side effects, forgetting to take the medication, fear and did not
want. An open-ended question was also provided to allow the patient to give reasons that were not on the list.
(3) Side effects perceived by the patient to be due to the oseltamivir medication. Side effects included nausea, vomiting, abdominal pain, itch, rash, nightmares, hallucinations, dizziness, headache, confusion and mood
changes. An open-ended question was included for patients to add in other side effects not on the list.
(4) Persistence of side effects after the regime was completed.
This included an open-ended question asking the patient to name the side effect(s) and the length of time after the regime that the side effect persisted.
A data collection form was also created to record dialysis and healthrelated information from patients' case notes. The following information were collected.
(1) Diagnosis of co-morbidities (hypertension, diabetes mellitus 2, ischaemic heart disease and hyperlipidaemia).
(2) Serum levels (haemoglobin and albumin).
(3) Urea reduction ratio (URR) (of HD patients) and KT/V measurements (of CAPD patients).
Single measurements from each participant's clinical files that were collected were from the months between June 2009 and January 2010. The cut-off points used in the dialysis clinics in Brunei and in this study for serum haemoglobin and albumin levels are 11 and 30 g/L, respectively, while those for URR and KT/V are 60% and 1.8, respectively.
Results
Overall, 441 of 478 nationwide dialysis patients had taken oseltamivir as prophylaxis, of which 75.1% (n = 331) had participated in the study. No patient was prematurely withdrawn from the treatment. The respondents' ages ranged from 23 to 87 years, with a mean of 52.0 and SD of 13.18. The demographic characteristics of the study respondents are shown below in Table 1 .
In the questionnaire, a list of side effects was given, of which the participating dialysis patients were asked to pick those that they had experienced, if any at all, during and after their prophylactic oseltamivir regime, which was over the course of a month. Five (1.5%) participants reported presence of side effects after their medications were finished. The frequency of participants that had reported side effects (experienced during the regime) was 25.7% (95% confidence interval: 21.0-30.0). This included 77 (26.9%) of the 286 HD participants and 8 (17.8%) of the 45 CAPD participants. Table 2 shows the frequency of each type of side effects by the study participants while on the oseltamivir regime (n = 331). The most prevalent side effect types reported by the respondents were nausea, dizziness and abdominal pain with frequencies of >9%. Table 3 shows factors that were associated with the frequency of side effects of oseltamivir when taken as prophylaxis by the study sample. Hypertension, diabetes mellitus, ischaemic heart disease and hyperlipidaemia were included as these were commonly associated or causal medical conditions of renal failure and could have acted as predisposing disorders to adverse effects. Serum haemoglobin and albumin levels, which are useful indicators of a patient's general well-being and nutritional state, were also included. Tables 4 and 5 show URR (for HD patients) and KT/V (for CAPD patients), respectively.
Gender, age, ethnicity, commonly associated medical conditions of renal failure, serum blood levels and KT/V and URR showed no significant association with the frequency of participants that had reported experiencing side effects. Table 6 shows the various reasons given by noncompliance group of the study population for not completing the medication regime. Results of our study showed that of the 331 patients, 35 (10.6%) had reported noncompliance to the antiviral medication in the survey, with perceived side effects of the medication and forgetting to take the medications found to be the two top reasons. There was no difference in the demographics of compliant and non-compliant patients.
Discussion
Roche reported the following list of the most frequent adverse effects that occurred in the prophylaxis of patients with normal renal function, which had incidence rates of ≥1%: nausea, headache, vomiting, diarrhoea, pain, fatigue, rhinorrhoea, abdominal pain, insomnia, dizziness (excluding vertigo), upper respiratory tract infection and dyspepsia [2] . Overall, our list of side effects is shorter than the list provided by Roche. This may be due to our lower overall dosage as compared to that used by Roche (75 mg once daily for at least 10 days). The differences in variety of side effects of both studies may reflect a difference between our study population and the population used by the earlier study in terms of age groups and sample size.
When comparing results of this present study with a previous study done by Robson et al. [8] , which saw 8 (66.7%) of their 12 HD patients and 10 (83.3%) of their 12 CAPD patients to have reported experiencing side effects, this present study showed a lower frequency of both HD and CAPD patients reporting side effects. The lower frequency could not be attributed to the difference in dosage regimes. Robson et al. adopted dosage regimens of 30 mg oseltamivir (once a week for CAPD patients and after alternate sessions in patients undergoing HD), which were lower dosages compared to the dosage in this present study. The difference could perhaps be due to the difference in sample sizes. This present study included almost all the dialysis patients in Brunei and would have included a wider spectrum of patients in terms of clinical profile, thus increases the credibility of our results over that of Robson et al.
The report made by Roche [2] states that dosage adjustments need not be made for the elderly, based on drug exposure and tolerability in the elderly of the general public. Roche reported that there was no clinical difference in side effects experienced by the elderly and the younger patient. However, the report by Roche goes on to say that this does not apply if the geriatric patient has co-existent renal impairment. In our present study, results showed no significant association between age and side effects frequency, disagreeing with the statement made by Roche. Differences in severity of side effects between young and old participants were not assessed, however.
In the study made by Robson et al. [8] , patients with severe and/or unstable co-morbidities were excluded. It did not go on to mention what these co-morbidities were or what they meant by severe and unstable. In this present study, presence of certain co-morbidities (hypertension, diabetes mellitus 2, ischaemic heart disease and hyperlipidaemia) of patients was taken as part of our analysis, which showed that they had no significant associations with frequency of participants reporting side effects. Severity of each patient's co-morbidity was not taken into account, however. No reports have been produced by Roche on the use of oseltamivir in patients with specific illnesses, such as those mentioned here.
The result of this study showed that 16 (43.2%) of the 37 non-compliant participants had reported side effects. From the current results, compliance was found to be significantly poorer among those who reported side effects as compared to those who did not. This suggests that side effects due to the medication to be one of the major contributing factors to non-compliance in the regimen. Despite this result, it is likely that the side effects were relatively mild. This is reflected by the 70 (82.4%) of the 85 patients who had reported side effects and still continued taking their medications. Two hundred and ninety-four (88.8%) of the 331 sample participants completed the full course of the first oseltamivir prophylactic regime against H1N1 (influenza A) in Brunei. The result of this survey thus shows that high compliance can be achieved with the current dosing model.
There were several limitations identified in the course of this study. More demographic questions could have been entered into the questionnaire that would have been relevant in our statistical analysis. A time lapse of about 2 months between start of the prophylactic regime and start of study could have reduced the accuracy of answers provided by the participants on the questionnaire.
The culture in Brunei, which is conservative and noncritical in nature, might have led participants to be reluctant to reveal their side effects. Some of the participants might have a lack of knowledge of being prescribed the prophylactic medication, in particular the geriatric participants. Also, it is possible that in some cases, patients may have attributed symptoms due to poor renal conditions or other co-morbidities to the use of oseltamivir. However, this is not likely to account for all the side effects experienced during the regime. A placebo group for the regime doses was not created in this study and so did not allow for comparison of frequencies of side effects and help ascertain true side effects of the regime doses.
More research should be done on the severity of side effects associated with oseltamivir in the patient with renal failure, especially its association with age of the renal patient (between the young and geriatric dialysis patients). Future research should focus on the effects of different types of co-morbidities of the renal failure patient or other types of medical conditions on oseltamivir side effects and vice versa. Research should also be done to find out if oseltamivir can be carried out for patients with very low levels of haemoglobin and albumin and also low levels of URR and KT/V.
Conclusions
In conclusion, despite the lack of solid evidence such as pharmacokinetic parameters to support the use of the current dosing regimen in both CAPD and HD patients, our study has demonstrated that the side effects reported were tolerable by the participants and was less in comparison with past studies such as that of Robson et al. [8] .
These results, together with the fact that there were no additional H1N1 cases reported in the dialysis group that underwent the regime, show that it is reasonable to assume that the current dosing regimen of 75 mg every 5 days in both CAPD and HD patients is both well tolerated and effective in providing prophylaxis to dialysis patients. The study suggests that the current dosing regimen is suitable for use in future prophylactic regimes of dialysis patients. The decision to provide prophylaxis to our dialysis population is controversial. This government policy has been deliberated carefully by our Ministry of Health and was felt necessary to protect the health of our dialysis patients. The scope of this study is not to recommend a prophylaxis practice for H1N1 but to provide a source of information on the side effect profile to be expected in similar regimes carried out in the future. As this is, to our knowledge, the largest study of its kind on end-stage renal failure patients, it thus contributes useful information regarding the use of oseltamivir prophylaxis in the patient with renal failure.
